Role of the Striatum and Hippocampus on Different Time Scales
Role of the Striatum and Hippocampus on Different Time Scales
Time processing is fundamental to survival and goal reaching in humans. Different time scales (seconds, minutes, and beyond) are processed through specific cognitive processes involving different neural representations. It is generally agreed that time scale in seconds-to-minutes range named "interval timing" would be anatomically linked to the striatum. Indeed, it is possible to demonstrate a deficit of interval timing processes in patients suffering from striatal damage (Huntington's disease). However, recent findings show involvement of a second brain structure, the hippocampus, in interval timing processing in the minutes range, suggesting an interaction between the striatum and hippocampus. Presumably, patients with hippocampal damage (Alzheimer's disease) would specifically show a decrease in performance for this minutes-range time scale. This study aims to provide a better understanding of the role of the striatum in the treatment of time and its interactions with other brain structures such as the hippocampus. More specifically, it is unclear whether the striatum plays a platform role that would always be involved regardless of the time scale, as suggested by the unified model of time or whether different brain structures is solicited according to the time scale, as suggested by the modular system model. In order to elucidate these issues, a potential double dissociation between brain structures and time scales will be tested.
In that aim, we will evaluate patients with Huntington's disease and patients with Alzheimer's disease by developing and using time processing paradigms comparing short and long time scales.
Inclusion Criteria:
Huntington's disease gene carriers
Patient included in the BioHD protocol
Age from 18 to 90 years old
Symptomatic patient
TFC ≥ 11
UHDRS motor> 5
Native language: French
Affiliation to a social security or to another social protection
Signature of informed consent
• Patients with Alzheimer's disease
MMS from 20 to 26 (included)
Age: from 60 to 90 years old
Native language: French
Progressive deterioration of memory reported by patient or caregiver for more than 6 months
Profile at RL /RI 16: no significant improvement with indexing
Episodic memory disorder isolated or associated with other cognitive disorders
MRI: Atrophy of the median temporal lobe
Affiliation to a social security or to another social protection
Signature of informed consent
• Healthy subjects
Healthy subject included in the BioHD protocol
MMS ≥ 26
Age from 18 to 90 years old
Native language: French
Affiliation to a social security or to another social protection
Signature of informed consent
Exclusion Criteria:
Huntington's disease gene carriers
Patients with Alzheimer's disease
Healthy subjects
anne-catherine.bachoud-levi@aphp.fr01 49 81 23 10 ext. +33
laurie.lemoine@aphp.fr01 49 81 21 11 ext. +33